Alkermes Vivitrex gets priority review
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Alkermes' Vivitrex has a Sept. 30 user fee date following FDA's priority review designation for the long-acting naltrexone injection. Vivitrex would be the first once-monthly injection product for treatment of alcoholism; Alkermes has been highlighting the formulation's potential compliance benefit over current alcoholism treatments, most of which are oral (1Pharmaceutical Approvals Monthly April 2005, p. 8). Vivitrex utilizes the company's Medisorb microsphere delivery technology...
You may also be interested in...
Vivitrex 90-day extension
FDA's user fee deadline for Cephalon/Alkermes' once-monthly injectable naltrexone formulation Vivitrex is Dec. 30 following a 90-day extension, the firms announce Sept. 20. The extension stems from a recent response being reclassified as a major amendment. Vivitrex is receiving a priority review for treatment of alcoholism (1Pharmaceutical Approvals Monthly June 2005, In Brief)...
Alkermes Files Vivitrex NDA; Alcoholism Drug May Have Compliance Benefit
Alkermes' Vivitrex is on to track to become the first once-monthly injection for alcohol dependence, providing a potential advantage for patient-compliance monitoring over competitors, the firm says
Cosmetic And Personal Care Trademark Review: 16 April
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.